Unexpectedly, a subsequent retrospective study reported that there was a positive correlation between PAK4 and hENT1 in clinical samples and a negative correlation between PAK4 and a poor prognosis, which brought a trace of uncertainty to the use of PAK4 as a clinical therapeutic target for pancreatic cancer [146]. This evidence concerns the gene PAK4 and familial pancreatic carcinoma.